Negative impact of corticosteroid use on outcome in patients with advanced <scp>BTCs</scp> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
Federica Lo Prinzi(Campus Bio Medico University Hospital), L. Bartalini(Azienda Ospedaliera Universitaria Pisana), Silvia Camera(Vita-Salute San Raffaele University), M.G. Polito(Campus Bio Medico University Hospital), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Tiziana Pressiani(IRCCS Humanitas Research Hospital), Guido Giordano(University of Foggia), Monica Verrico(Policlinico Umberto I), Oluseyi Abidoye(Mayo Clinic), Francesca Salani(Scuola Superiore Sant'Anna), Emiliano Tamburini(Ospedale Infermi di Rimini), Anna Saborowski(Medizinische Hochschule Hannover), Alessandro Pastorino(Ospedale Policlinico San Martino), Fabian Finkelmeier(Goethe University Frankfurt), Alessandro Parisi(Marche Polytechnic University), Mario Scartozzi(University of Cagliari), Gerald W. Prager(Comprehensive Cancer Center Vienna), Lukas Perkhofer(University Hospital Ulm), Ricardo Roque, Giovanni Farinea(University of Turin), Florian Castet(Institut d'Investigació Biomédica de Bellvitge), Gian Paolo Spinelli(Sapienza University of Rome), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Stephen L. Chan(Chinese University of Hong Kong), Chiara Braconi(Beatson West of Scotland Cancer Centre), Marta Schirripa(Azienda Sanitaria Locale Viterbo), Anna Diana(University of Campania "Luigi Vanvitelli"), Jessica Lucchetti(Campus Bio Medico University Hospital), Jorge Adeva(Hospital Universitario 12 De Octubre), Nicola Personeni(IRCCS Humanitas Research Hospital), Maria Grazia Rodriquenz(Casa Sollievo della Sofferenza), Ester Oneda(Fondazione Poliambulanza Istituto Ospedaliero), Federico Rossari(Vita-Salute San Raffaele University), Hong Jae Chon(CHA University Bundang Medical Center), Chiara Gallio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Ingrid Garajová(University of Parma), Cecilia Melo Alvim(Hospital de Santa Maria), Aitzaz Qaisar, Tomoyuki Satake(National Cancer Center Hospital East), Frederik Peeters, Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Changhoon Yoo(Ulsan College), Jin Won Kim(Korea University Medical Center), Il Hwan Kim(Inje University Haeundae Paik Hospital), Emanuela Di Giacomo(Campus Bio Medico University Hospital), Mario Domenico Rizzato(Istituto Oncologico Veneto), Nuno Couto(Champalimaud Foundation), Silvana Leo(Ospedale Vito Fazzi), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi)
Cited by 4
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k